Squarepoint
VYNE icon

Squarepoint’s VYNE Therapeutics VYNE Stock Holding History

Squarepoint’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-78,474
Closed -$129K – 5067
2025
Q2 		$129K Buy
+78,474
New +$102K ﹤0.01% 4100
2021
Q2 		– Sell
-977
Closed -$120K – 3739
2021
Q1 		$120K Sell
977
-6,586
-87% -$955K ﹤0.01% 2859
2020
Q4 		$860K Buy
7,563
+6,953
+1,140% +$874K 0.01% 1445
2020
Q3 		$73K Buy
+610
New +$71.2K ﹤0.01% 2330
2020
Q1 		– Sell
-278
Closed -$93K – 2571
2019
Q4 		$93K Sell
278
-175
-39% -$58.3K ﹤0.01% 2354
2019
Q3 		$146K Sell
453
-53
-10% -$17.1K ﹤0.01% 2143
2019
Q2 		$218K Buy
506
+228
+82% +$113K ﹤0.01% 2077
2019
Q1 		$157K Buy
278
+80
+40% +$38.4K ﹤0.01% 1986
2018
Q4 		$59K Sell
198
-187
-49% -$83.7K ﹤0.01% 1839
2018
Q3 		$273K Buy
+385
New +$238K ﹤0.01% 1588

Other funds holding VYNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Squarepoint's VYNE Position: Q3 2025 in Review

Squarepoint sold out of VYNE Therapeutics (VYNE) in Q3 2025, closing a stake of 78,474 shares — an estimated $129K sold.

Squarepoint first reported a position in VYNE in Q3 2018 and held it in 10 quarters. The position peaked at $860K in Q4 2020. 36 funds tracked by Wall St. Rank hold VYNE as of Q3 2025.

  • Squarepoint reported no remaining VYNE Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Squarepoint sold 78,474 VYNE Therapeutics shares in Q3 2025, an estimated $129K.
  • Squarepoint first reported a position in VYNE Therapeutics in Q3 2018 and held it in 10 quarters.
  • Squarepoint's VYNE Therapeutics position peaked at $860K in Q4 2020.
  • 36 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.